Clinical trial: Combination allopurinol‐thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study)
Alimentary Pharmacology & Therapeutics · 2024-02 · 59 (4) · 504-514
DOI: 10.1111/apt.17831 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 14.12.2023. Verfasst von Abhinav Vasudevan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Eastern Health, Box Hill, Victoria, Australia. Hauptthemen laut MEDLINE: Azathioprine, Inflammatory Bowel Diseases, Purines, Sulfhydryl Compounds. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Thiopurines are established treatments for inflammatory bowel disease (IBD), yet concerns remain regarding their safety.
Aim
To evaluate the use of thiopurine‐allopurinol combination therapy compared to standard thiopurine therapy in IBD.
Methods
We performed a multicentre, randomised, placebo‐controlled trial to compare the efficacy and safety of thiopurine‐allopurinol versus thiopurine with placebo for adults commencing a thiopurine for IBD. Patients had active disease at baseline; dosing of therapy was based on a pre‐specified regimen and subsequent metabolites. The primary outcome was the proportion of patients achieving a composite of symptomatic disease activity remission (Harvey Bradshaw Index
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Eastern Health, Box Hill, Victoria, Australia.
- Monash University, Eastern Health Clinical School, Box Hill, Victoria, Australia.
- Department of Gastroenterology, The Austin Hospital, Melbourne, Victoria, Australia.
- Department of Medicine, Austin Academic Centre, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Gastroenterology, Central Clinical School, Monash University and Alfred Health, Melbourne, Victoria, Australia.
- Department of Gastroenterology, Northern Health, Epping, Victoria, Australia.
ORCID-Profile: Abhinav Vasudevan, Danny Con, Peter De Cruz, Miles P Sparrow, Antony B Friedman, Daniel R van Langenberg
Zitieren
APA
Vasudevan, A., Con, D., De Cruz, P., Sparrow, M. P., Friedman, A. B., Garg, M., Kashkooli, S., Gibson, P. R., & van Langenberg, D. R. (2024). Clinical trial: Combination allopurinol‐thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study). Alimentary Pharmacology & Therapeutics, 59(4), 504-514. https://doi.org/10.1111/apt.17831
Vancouver
Vasudevan A, Con D, De Cruz P, Sparrow MP, Friedman AB, Garg M, et al. Clinical trial: Combination allopurinol‐thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study). Alimentary Pharmacology & Therapeutics. 2024;59(4):504-514. doi:10.1111/apt.17831
BibTeX
@article{Vasudevan2024,
author = {Vasudevan, Abhinav and Con, Danny and De Cruz, Peter and Sparrow, Miles P and Friedman, Antony B and Garg, Mayur and Kashkooli, Soleiman and Gibson, Peter R and van Langenberg, Daniel R},
title = {Clinical trial: Combination allopurinol‐thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study)},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {59},
number = {4},
pages = {504--514},
doi = {10.1111/apt.17831}
}
EUVIMED